86 related articles for article (PubMed ID: 18384260)
41. Pharmacogenetic considerations in the treatment of psychiatric disorders.
Lohoff FW; Ferraro TN
Expert Opin Pharmacother; 2010 Feb; 11(3):423-39. PubMed ID: 20102306
[TBL] [Abstract][Full Text] [Related]
42. Beyond genomics.
Dollery CT
Clin Pharmacol Ther; 2007 Oct; 82(4):366-70. PubMed ID: 17851575
[TBL] [Abstract][Full Text] [Related]
43. Genaissance pharmaceuticals, inc.
Oestreicher P
Pharmacogenomics; 2002 Mar; 3(2):273-6. PubMed ID: 11972448
[TBL] [Abstract][Full Text] [Related]
44. Awareness survey of parties involved in pharmacogenomics in Japan.
Tamaoki M; Gushima H; Tsutani K
Pharmacogenomics; 2007 Mar; 8(3):275-86. PubMed ID: 17324116
[TBL] [Abstract][Full Text] [Related]
45. Pharmacogenomic biomarkers: new tools in current and future drug therapy.
Sim SC; Ingelman-Sundberg M
Trends Pharmacol Sci; 2011 Feb; 32(2):72-81. PubMed ID: 21185092
[TBL] [Abstract][Full Text] [Related]
46. Pharmacogenetics--where are we and where are we heading?
Kola I
Pharmacogenomics; 2005 Dec; 6(8):793-5. PubMed ID: 16296941
[No Abstract] [Full Text] [Related]
47. Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation.
Duconge J; Ruaño G
Pharmacogenomics; 2015; 16(15):1685-8. PubMed ID: 26431456
[No Abstract] [Full Text] [Related]
48. The phenotypic screening pendulum swings.
Mullard A
Nat Rev Drug Discov; 2015 Dec; 14(12):807-9. PubMed ID: 26620403
[No Abstract] [Full Text] [Related]
49. Freely available software programs for drug discovery.
Klon AE
Curr Top Med Chem; 2012; 12(18):1945. PubMed ID: 23110529
[No Abstract] [Full Text] [Related]
50. Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic
Saldarreaga Marin A; Cendros M; Ciudad CJ; Sabater A
Pharmgenomics Pers Med; 2021; 14():963-970. PubMed ID: 34408471
[TBL] [Abstract][Full Text] [Related]
51. Avoidable drug-gene conflicts and polypharmacy interactions in patients participating in a personalized medicine program.
Reynolds KK; Pierce DL; Weitendorf F; Linder MW
Per Med; 2017 May; 14(3):221-233. PubMed ID: 29767587
[TBL] [Abstract][Full Text] [Related]
52. Toward personalized medicine in the neuropsychiatric field.
Wong EH; Fox JC; Ng MY; Lee CM
Int Rev Neurobiol; 2011; 101():329-49. PubMed ID: 22050858
[TBL] [Abstract][Full Text] [Related]
53. Genelex Corporation.
Coleman H; Ashcraft K
Pharmacogenomics; 2008 Apr; 9(4):469-75. PubMed ID: 18384260
[TBL] [Abstract][Full Text] [Related]
54. Developing pharmacogenetic evidence throughout clinical development.
Burns DK
Clin Pharmacol Ther; 2010 Dec; 88(6):867-70. PubMed ID: 20981004
[TBL] [Abstract][Full Text] [Related]
55. Helicos BioSciences.
Milos P
Pharmacogenomics; 2008 Apr; 9(4):477-80. PubMed ID: 18384261
[TBL] [Abstract][Full Text] [Related]
56. Personalized medicine: elusive dream or imminent reality?
Lesko LJ
Clin Pharmacol Ther; 2007 Jun; 81(6):807-16. PubMed ID: 17505496
[TBL] [Abstract][Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
